I'm intrigued: I think this is basically the use of a composite to increase efficiency, thus converting the "non-significant" mortality result to "significant" because death = 0 utility. Am I wrong? https://t.co/XuAXPdHYHJ (Table 4--death censored analysis
4,121 followers
1,896 followers
@ogi_gajic @VPrasadMDMPH @medevidenceblog @djkor1 Re-purposing of drugs not uncommon regardless of primary indication - lots of examples. Not sure incentives have influenced the use of a generic drug which costs pennies (cents). Science should continue to
4,233 followers
RT @RespiratoryBMC: Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness f... https…
580 followers
RT @RespiratoryBMC: Simvastatin for patients with acute respiratory distress syndrome: long-term outcomes and cost-effectiveness f... https…